National Health (April 2022 First New Brand statutory price reduction) (Exercise of Ministerial discretion) Determination 2022 (Cth)

National Health (April 2022 First New Brand statutory price reduction) (Exercise of Ministerial discretion) Determination 2022 National Health Act 1953

I, Nikolai Tsyganov, Acting Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health and Aged Care make this determination under subsection 99ACF(3AA) of the National Health Act 1953.

Dated 29 March 2022

NIKOLAI TSYGANOV Acting Assistant Secretary Pricing and PBS Policy Branch Technology Assessment and Access Division Department of Health

1 Name of Determination This instrument is the National Health (April 2022 First New Brand statutory price reduction) (Exercise of Ministerial discretion) Determination 2022.

2 Commencement This instrument commences on 1 April 2022. 3 Definition

Note: A number of expressions used in this instrument are defined in Part VII the Act,

In this instrument:

Act means the National Health Act 1953. 4 Authority

This instrument is made under subsection 99ACF(3AA) of the Act. 5 Brand of pharmaceutical item with approved ex-manufacturer price not reduced

I determine under subsection 99ACF(3AA) of the Act that, for the purposes of subsection 99ACF(2AB), the approved ex-manufacturer price that comes into force on 1 April 2022 of the brand of pharmaceutical item specified in column 2 as an item in the table in Schedule 1 is to be worked out using a reduction of zero %.

Schedule 1— Brand of pharmaceutical item with approved ex-manufacturer price not reduced

Column 1 Column 2 Item Brand of Pharmaceutical Item Drug Form Manner of administration Brand 1 Lacosamide Oral solution 10 mg per mL, 200 mL Oral Vimpat